Holen Sie sich die Stockscreener-App
8.21
6.76%
0.52
Handel nachbörslich:
8.21
Schlusskurs vom Vortag:
$7.69
Offen:
$7.52
24-Stunden-Volumen:
625.54K
Relative Volume:
1.52
Marktkapitalisierung:
$579.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.70M
KGV:
-3.7661
EPS:
-2.18
Netto-Cashflow:
$-86.54M
1W Leistung:
-3.64%
1M Leistung:
-6.06%
6M Leistung:
+17.12%
1J Leistung:
-3.75%
1-Tages-Spanne:
$7.44
$8.25
1-Wochen-Bereich:
$7.41
$8.615
52-Wochen-Spanne:
$6.33
$16.65
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.21 | 579.35M | 0 | -100.70M | -86.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.29 - MarketBeat
Dominic Piscitelli Sells 8,851 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
Pratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $204,184.80 in Stock - MarketBeat
Oric Pharmaceuticals chief medical officer sells $73,293 in stock - Investing.com India
Oric Pharmaceuticals chief medical officer sells $73,293 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CFO sells $73,297 in stock - Investing.com India
Oric Pharmaceuticals CFO sells $73,297 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock - Investing.com
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock By Investing.com - Investing.com UK
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownTime to Sell? - MarketBeat
(ORIC) Technical Data - Stock Traders Daily
Charles Schwab Investment Management Inc. Boosts Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (STU:4TZ) Operating Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Fmr LLC Decreases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Position Lowered by Fmr LLC - MarketBeat
How to Take Advantage of moves in (ORIC) - Stock Traders Daily
ArrowMark Colorado Holdings LLC Acquires 80,986 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Fred Alger Management LLC Acquires 63,535 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Victory Capital Management Inc. Has $1.02 Million Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Consensus Price Target from Brokerages - Defense World
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC Pharmaceuticals to Present at Major Healthcare Conferences in December | ORIC Stock News - StockTitan
Long Term Trading Analysis for (ORIC) - Stock Traders Daily
ORIC Pharmaceuticals (STU:4TZ) GF Value Rank : 0 (As of Nov. 22, 2024) - GuruFocus.com
ORIC Pharmaceuticals (STU:4TZ) Enterprise Value : €327.63 Mil (As of Nov. 21, 2024) - GuruFocus.com
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside - MSN
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Research Analysts Issue Forecasts for ORIC FY2024 Earnings - Defense World
Oric Pharmaceuticals Inc (ORIC-Q) QuotePress Release - The Globe and Mail
Wedbush Lowers Earnings Estimates for ORIC Pharmaceuticals - Defense World
(ORIC) Trading Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World
Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks
Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com
Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com
ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World
ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World
Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology
ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia
ORIC-114 shows promise in preclinical cancer study - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):